Cargando…
Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
One of the defining features of heart failure (HF) is neurohormonal activation. The renin-angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause vasoconstriction and fluid retention and, in response, the secretion of natriuretic peptides (NPs) from volume and pressure-overl...
Autores principales: | Cuthbert, Joseph J, Pellicori, Pierpaolo, Clark, Andrew L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425097/ https://www.ncbi.nlm.nih.gov/pubmed/32848403 http://dx.doi.org/10.2147/TCRM.S234772 |
Ejemplares similares
-
The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020) -
Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges
por: Cuthbert, Joseph J, et al.
Publicado: (2022)